Table 1.

Clinical, drug, and cardiac data for patients

ParameterAll Patients (n = 246)No LVH (n = 89)LVH (n = 157)P
Age (yr; mean ± SD)51.4 ± 12.151.8 ± 12.251.2 ± 12.10.20
Male gender (n [%])157 (63.8)55 (61.8)102 (65.0)0.62
BMI (kg/m2; mean ± SD)25.6 ± 4.625.2 ± 4.225.8 ± 4.80.45
Ischemic heart disease (n [%])51 (20.7)21 (23.6)30 (19.1)0.40
Diabetes (n [%])156 (63.4)58 (65.2)98 (62.4)0.67
Chronic heart failure (n [%])15 (6.1)5 (5.6)10 (6.4)0.81
Cerebrovascular disease (n [%])20 (8.1)10 (11.2)10 (6.4)0.18
Peripheral vascular disease (n [%])18 (7.3)7 (7.9)11 (7.0)0.80
Hypertension (n [%])223 (90.7)79 (88.8)144 (91.4)0.44
Duration on HD (yr; mean ± SD)3.0 ± 3.02.9 ± 3.13.0 ± 2.90.89
UF volume (L; mean ± SD)2.2 ± 1.12.1 ± 0.92.3 ± 1.20.08
Pre-HD SBP (mmHg; mean ± SD)142.3 ± 21.8138.1 ± 24.3144.6 ± 20.00.02
Post-HD SBP (mmHg; mean ± SD)132.3 ± 23.1129.2 ± 24.8133.8 ± 21.90.14
Pre-HD DBP(mmHg; mean ± SD)79.8 ± 14.079.1 ± 16.480.3 ± 12.40.52
Post-HD DBP(mmHg; mean ± SD)73.3 ± 13.872.3 ± 15.973.9 ± 12.50.36
Pre-HD PP (mmHg; mean ± SD)62.5 ± 17.159.1 ± 17.664.4 ± 16.50.02
Post-HD PP (mmHg; mean ± SD)58.9 ± 17.657.1 ± 18.960.0 ± 16.80.22
URR (%; mean ± SD)70.8 ± 7.567.6 ± 11.970.7 ± 6.40.64
Hemoglobin (g/dl; mean ± SD)11.3 ± 1.311.3 ± 1.511.3 ± 1.30.95
Adjusted Ca (mmol/L; mean ± SD)2.31 ± 0.202.29 ± 0.202.31 ± 0.200.61
Phosphate (mmol/L; mean ± SD)1.27 ± 0.401.20 ± 0.401.32 ± 0.500.06
Ca × PO4 (mean ± SD)2.93 ± 1.002.72 ± 0.903.05 ± 1.000.03
Albumin (mean ± SD)37.3 ± 5.937.9 ± 6.136.9 ± 5.80.24
PTH (mean ± SD)32.5 ± 28.734.3 ± 28.331.4 ± 29.20.54
Aspirin (n [%])97 (39.4)38 (42.7)59 (37.6)0.43
Warfarin (n [%])11 (4.5)3 (3.8)8 (5.1)0.53
ACEI/ARB (n [%])61 (24.8)23 (25.8)38 (24.2)0.78
Diuretic (n [%])50 (20.3)23 (25.8)27 (17.2)0.11
CCA (n [%])73 (29.7)25 (28.1)48 (30.6)0.68
α Adrenoceptor blocker (n [%])17 (6.9)9 (10.1)8 (5.1)0.14
β Adrenoceptor blocker (n [%])106 (43.1)36 (40.4)70 (44.6)0.53
ESA (n [%])196 (79.7)74 (83.1)122 (77.7)0.46
Vitamin D analogue (n [%])99 (40.2)35 (39.3)64 (40.8)0.83
Ejection fraction (%; mean ± SD)64.7 ± 13.368.5 ± 7.962.6 ± 15.10.001
LVMI (g/m2; mean ± SD)99.4 ± 30.067.2 ± 10.8116.9 ± 31.30.001
EDV/BSA (ml/m2; mean ± SD)77.8 ± 31.158.2 ± 18.388.7 ± 34.70.001
ESV/BSA (ml/m2; mean ± SD)29.6 ± 21.919.7 ± 10.836.5 ± 27.50.001
LVSD (n [%])45 (18.3)6 (6.7)39 (24.8)0.001
LV dilation (n [%])39 (15.8)2 (2.2)37 (23.6)0.001
  • Comparisons between patients with and without LVH are shown. Tests of significance are t test and χ2 test. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II blocker; BMI, body mass index; CCA, calcium channel antagonist; ESA, erythropoiesis-stimulating agent; LVSD, left ventricular systolic dysfunction; MAP, mean arterial pressure; PP, pulse pressure.